TY - JOUR
T1 - Synthesis and biological evaluation of 9-thia-5,10-dideazafolic acid
AU - Wall, Mark
AU - Benkovic, Stephen J.
PY - 2002
Y1 - 2002
N2 - The folate analogue, 9-thia-5,10-dideazafolic acid (3b), was obtained in an efficient two-step procedure in an overall yield of 60%. The previously unknown intermediate dimethyl-thiocarbamic acid S-(2-amino-3,4-dihydo-4-oxo-pyrido[2,3-d] pyrimidin-6-yl) ester (5) was prepared via the condensation of 2,6-diamino-3H-pyrimidin-4-one and S-(2-malonaldehyde)-1,1,3,3-tetramethylthiouronium bromide (4). Compound 5, in a one pot procedure, was deprotected using sodium hydroxide and then coupled to diethyl N-[(4-chloromethyl)benzoyl]-L-glutamate, followed by saponification of the ethyl esters to give the 9-thia-5,10-dideazafolic acid (3b). Compound 3b was a potent inhibitor of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (Ki of 8 ± 5 μM) and showed no inhibition of human glycinamide ribonucleotide transformylase at concentrations as high as 50 μM. Compound 3b was screened by the National Cancer Institute Developmental Therapeutics Program against 60 human tumors and was found to be active against a leukemia RPMI-8226 cell line where the LC50 was 1 μM.
AB - The folate analogue, 9-thia-5,10-dideazafolic acid (3b), was obtained in an efficient two-step procedure in an overall yield of 60%. The previously unknown intermediate dimethyl-thiocarbamic acid S-(2-amino-3,4-dihydo-4-oxo-pyrido[2,3-d] pyrimidin-6-yl) ester (5) was prepared via the condensation of 2,6-diamino-3H-pyrimidin-4-one and S-(2-malonaldehyde)-1,1,3,3-tetramethylthiouronium bromide (4). Compound 5, in a one pot procedure, was deprotected using sodium hydroxide and then coupled to diethyl N-[(4-chloromethyl)benzoyl]-L-glutamate, followed by saponification of the ethyl esters to give the 9-thia-5,10-dideazafolic acid (3b). Compound 3b was a potent inhibitor of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (Ki of 8 ± 5 μM) and showed no inhibition of human glycinamide ribonucleotide transformylase at concentrations as high as 50 μM. Compound 3b was screened by the National Cancer Institute Developmental Therapeutics Program against 60 human tumors and was found to be active against a leukemia RPMI-8226 cell line where the LC50 was 1 μM.
UR - http://www.scopus.com/inward/record.url?scp=0036744899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036744899&partnerID=8YFLogxK
U2 - 10.1002/jhet.5570390541
DO - 10.1002/jhet.5570390541
M3 - Article
AN - SCOPUS:0036744899
SN - 0022-152X
VL - 39
SP - 1097
EP - 1099
JO - Journal of Heterocyclic Chemistry
JF - Journal of Heterocyclic Chemistry
IS - 5
ER -